Sign In
Buy CYCN
$3.00
-0.0200 (-0.662%)
At Close: Jun 03, 2026
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
03:30pm, Thursday, 09'th Apr 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
02:45pm, Thursday, 02'nd Apr 2026
NEW YORK, April 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
01:08am, Thursday, 02'nd Apr 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the p
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
04:53pm, Wednesday, 01'st Apr 2026
MILWAUKEE, April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction w
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing
10:53am, Wednesday, 01'st Apr 2026
Under the deal, the combined company is expected to operate as Korsana Biosciences and trade on the Nasdaq under the ticker symbol KRSA. The move appears to be driving enthusiasm because it gives publ
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
09:52am, Wednesday, 01'st Apr 2026
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
07:05am, Wednesday, 01'st Apr 2026
WALTHAM, Mass.--(BUSINESS WIRE)---- $CYCN--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discoveri
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders acr
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)
02:08am, Tuesday, 06'th Jan 2026
BeyondSpring (NASDAQ: BYSI - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Pr
Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ)
01:26am, Wednesday, 31'st Dec 2025
Response Genetics (OTCMKTS:RGDXQ - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get Free Report) are both medical companies, but which is the better stock? We will compare the two compa
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call
12:53pm, Wednesday, 24'th Sep 2025
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call Company Participants Regina Graul - CEO, President & Director Presentation Regina Graul CEO, President & Director Good morning, everyone. Yeste
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
04:01pm, Tuesday, 23'rd Sep 2025
Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
08:08am, Tuesday, 17'th Dec 2024
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth.
